Sold as Medihaler Ergotamine. Every FDA application for this active ingredient: 1 branded and 3 generic.
As of Nov 16, 2026, FDA lists 4 applications for Ergotamine Tartrate (sold as Medihaler Ergotamine), first approved Jan 13, 1960, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Ergomar | Part D | $2.2M | +939% | 311 |
| Jan 13, 1960 | Medihaler ErgotamineNDA 12102 · New dosage form | 3m | 2 | Discontinued |
| Jul 29, 1982 | WigrettesANDA 86750 | Organon USA Inc | 0 | Discontinued |
| Sep 25, 1992 | ErgomarANDA 87693 | Pangea | 13 | Marketed |
| — | ErgostatANDA 88337 | Watson Labs Inc | 6 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA